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The following study demonstrated that, in in vitro differentiated neurons, SIRT1 silencing induced an increase of IGF-1 protein expression
and secretion and of IGF-1R protein levels which, in turn, prolonged neuronal cell survival in presence of an apoptotic insult. On the
contrary, SIRT1overexpression increased cell death. In particular, IGF-1 and IGF-1R expression levelswere negatively regulated by SIRT1.
In SIRT1 silenced cells, the increase in IGF-1 and IGF-1R expression was associated to an increase in AKT and ERK1/2 phosphorylation.
Moreover, neuronal differentiation was reduced in SIRT1 overexpressing cells and increased in SIRT1 silenced cells. We conclude that
SIRT1 silenced neurons appearmore committed to differentiation andmore resistant to cell death through the activation of IGF-1 survival
pathway.
J. Cell. Physiol. 228: 1754–1761, 2013.  2013 Wiley Periodicals, Inc.
SIRT1 is a member of the SIR2-like gene family that encodes for
sirtuins, a class III histone deacetylases and/or mono-ADP-
ribosyltransferases. Sirtuins affect many metabolic and stress
resistance pathways (Guarente, 2011). In mammals, there are
seven sirtuins (SIRT1 to SIRT7) with different functions and
different cellular localization (Guarente, 2011). By using
nicotinamide adenine dinucleotide (NADþ) as their activating
cofactor, they are able to sense energy availability, circadian
rhythms and cellular stresses. Sirtuins respond to metabolic or
toxic stresses by deacetylating several cellular factors. SIRT1
deacetylates many histonic and non histonic proteins such as
p53 (Vaziri et al., 2001; Langley et al., 2002), the forkhead
transcription factors (FOXOs; Motta et al., 2004), nuclear
factor kappa-light-chain (NF-kB; Yeung et al., 2004) and
peroxisome proliferator-activated receptor gamma
coactivator 1-alpha (PGC-1a; Nemoto et al., 2005). SIRT1 is
also involved in neuronal degeneration. SIRT1 can be
neuroprotective or neurotoxic depending on conditions,
cellular stress and cellular type. SIRT1 has been shown to be
protective against neuronal apoptosis in cerebellar granule
neurons (Pﬁster et al., 2008), in the axonal Wallerian
degeneration model (Araki et al., 2004), in Alzheimer disease
(AD) models (Qin et al., 2006; Kim et al., 2007) and in cortical
neurons (Hasegawa and Yoshikawa, 2008). In addition, SIRT1
improves learning and memory by activating the brain-derived
neurotrophic factor (BDNF) gene (Gao et al., 2010). SIRT1
neurotoxicity has been also documented. SIRT1
overexpression in mice induced a memory deﬁcit, and had no
neuroprotective effects against damage induced by ischemia or
by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP;
Kakefuda et al., 2009). Moreover, caloric restriction (CR)
causes both SIRT1 increased expression in some regions of the
brain (such as the hypothalamus), and SIRT1 downregulation in
others (Chen et al., 2008; Liu et al., 2008). In addition, SIRT1
chemical inactivation has been shown to be beneﬁcial in
neurons (Chong et al., 2005;Holland et al., 2008; Liu et al., 2008,
2009; Tang, 2010).
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Insuline like growth factor-1 (IGF-1) affects cellular survival,
metabolism and glucose homeostasis by activating the Ser/Thr-
kinase B/AKT pathway (Laviola et al., 2007). IGF-1 plays also a
role in the central nervous system (Broughton and Partridge,
2009). In the brain IGF-1 promotes neuron survival, neurite
outgrowth, maturation of oligodendrocytes, myelination
(D’Ercole et al., 1996), and improves learning andmemory (Van
der Heide et al., 2006). Alteration of IGF-1 protein expression
has been associatedwith neurodegenerative pathologies (Trejo
et al., 2004) andwith cognitive decline during aging (Markowska
et al., 1998). In addition, IGF-1 has been shown to posses
neuroprotective and neurogenic function during ischemic brain
injury (Guan et al., 2001, 2003). IGF-1 acts as neuroprotective
factor by inducing NF-kB via PI 3-kinase pathway (Heck et al.,
1999).
Previously, we observed that neuronal differentiated
NG108-15 cells are more resistant to STS-induced apoptosis
(Pucci et al., 2008). The acquired resistance of the differentiated
cellular phenotype depends on an increased IGF-1 expression/
secretion and consequent activation of survival pathways (Pucci
et al., 2008). Several authors have highlighted the connection
between SIRT1 and IGF-1 pathways (Bordone et al., 2006; Li
et al., 2008; Longo, 2009). Therefore, we hypothesized a role
for SIRT1 in regulating IGF-1 survival pathway in in vitro
differentiated neurons.
In the following study, we investigated the interplay between
SIRT1 and IGF-1 pathways in neuronal cell death. SIRT1 protein
level modulation in in vitro differentiated NG108-15 cells
altered neuronal differentiation and resistance to several death
stimuli. In particular, SIRT1 silencing activated IGF-1 pathway by
Fig. 1. SIRT1 modulation in NG108-15 cells. A: Reduced sensitivity of NaB differentiated NG108-15 cells to Sirtinol. Proliferating and NaB
differentiated cells were either left untreated or treated with 50mMSirtinol for 24 h. Morphology was evaluated by phase contrast microscopy.
Picturesweretakenat20Twithadigitalcameraonaninvertedmicroscope.Percentageofcelldeath indicated ineach imagewascalculatedbyﬂow
cytometryanalysisofthreeindependentexperiments.CU controluntreatedcells.M,P<0.05.B:DecreasedSIRT1expressioninNaBdifferentiated
NG108-15 cells. Proliferating and NaB differentiated cells were lysed and SIRT1 levels measured by Western Blot. b-actin was used as loading
control. C: SIRT1overexpression and silencing inNG108-15 cells. Stable clones overexpressing Flag-taggedSIRT1were obtained by transfecting
NG108-15cellswithapcDNA3.1-FlagSIRT1as indicated inMaterialsandMethodsSection.Atthesametime, stableclonessilencedforSIRT1were
obtained by transducing NG-108-15 cells with lentiviral particles expressing SIRT1-shRNA as indicated under Materials and Methods Section.
SIRT1overexpressionwasmeasuredwith ananti-Flag antibody (left side). SIRT1silencingwasmeasuredwithananti-SIRT1antibody (right side).
b-actinwas used as loading control. D:Global protein lysine acetylation levels in SIRT1overexpressing and silencedNG108-15 cells. Proliferating
and NaB differentiated wt, SIRT1 overexpressing and SIRT1 silenced cells were lysed and global acetylation state of lysines was measured by
Western blot. Results are representative of three independent experiments. E: p53 acetylation levels in wt, SIRT1 overexpressing and SIRT1
silenced NG108-15 cells. Proliferating and NaB differentiated wt, SIRT1 overexpressing and SIRT1 silenced cells were lysed and p53 acetylation
statewasmeasuredbyWesternBlotasdescribed inMaterialsandMethodsSection.Resultsarerepresentativeof three independentexperiments.
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increasing IGF-1 secretion and IGF-1R expression levels. SIRT1
silenced neurons appeared, therefore, more committed to
differentiation and more resistant to cell death through the
activation of IGF-1 survival pathway.
Materials and Methods
Materials
Unless stated otherwise reagents were purchased from Sigma–
Aldrich (St. Louis, MO). Sorbitol was dissolved directly in cell
culture medium as 1mM solution. Staurosporine (STS) was
dissolved in dimethyl sulfoxide (DMSO) as 1mM stock solution.
Sirtinol was dissolved in DMSO as 25mM stock solution.
Camptothecin was dissolved in DMSO as 25mM stock solution.
Thapsigargin was dissolved inDMSO as 1mM stock solution. IGF-1
was dissolved as 50 ng/ml solution in H2O. Sodium butyrate (NaB)
was dissolved as 0.5M solution in H2O. Propidium Iodide (PI) was
dissolved as 100mg/ml in H2O. Collagen I was dissolved as 100mg/
ml solution in H2O. Dulbecco’s modiﬁed Eagle’s medium (DMEM)
without pyruvate and HAT supplement were purchased from
Invitrogen Life Technologies (Carlsbad, CA). FBS was purchased
from Sigma–Aldrich. Anti-Actina-b polyclonal antibody was
purchased fromSpring Bioscience (Pleasanton, CA). AntiMAP51B-
MAP5 monoclonal antibody was purchased from GENETEX (San
Antonio, TX). Anti IGF-1 monoclonal antibody was purchased
from ABcam (Cambridge, UK). Anti-IGF-1-receptor (IGF-1R)-b
and anti acetyl-p53 (lys379) polyclonal antibodies were purchased
from Cell Signalling Technology, Inc. (Danvers, MA). Anti
Acetylated Lysine polyclonal antibody, HRP Conjugate was
purchased from Assay Designs (Ann Arbor, MI). Anti-Akt
polyclonal antibody, anti-phospho-Akt polyclonal antibody
(Thr308), anti-ERK1/2 polyclonal antibody and anti-phospho-
ERK1/2 polyclonal antibody (Tyr202/Thr204) were purchased
from Invitrogen (Milan, Italy). Anti-Sirt1 polyclonal antibody and
Anti-Tubulin monoclonal antibody were purchased from Santa
Cruz Biotechnology, Inc. (Santa Cruz, CA). An enhanced
chemiluminescent detection system (ECL kit) was purchased from
Euroclone (Milan, Italy).
Cell culture
The cell line NG108-15 (mouse neuroblastoma/rat glioma hybrid
cell line) was purchased from ATCC (Manassas, VA) and grown in
DMEM medium supplemented with 10% (v/v) FBS and HAT
supplement. For differentiation experiments, cells were plated on
collagen I on plastic dishes (100mm 20mm) and cultured in
DMEM without pyruvate supplemented with 2% FBS for 5 days in
presence of 1mM NaB. Medium was changed every other day.
Cultures were maintained at 378C in a humidiﬁed atmosphere of
5% CO2 and 95% air.
Stable transfections
Sirt1 cDNA clonewas purchased fromOrigeneCompany (Catalog
No: RC218134-20). Transfections were performed with TransIT-
Neural Transfection Reagent (MIRUS, Madison, WI) according to
themanufacturer’s protocols. Stable overexpressing cell lineswere
selected by adding 350mg/ml of Geneticin G-418 Sulphate
(Invitrogen, Paisley, UK) to the fresh complete medium.
Lentiviral transduction
MissionTM TRC shRNA lentiviral transduction particles expressing
short hairpin RNA (shRNA) targeting SIRT1 was purchased from
Sigma–Aldrich. Stably transduced cloneswere generated according
to the manufacturer’s instructions. Brieﬂy, cells were seeded on a
24-well plate. The following day cells were infected. After 24 h
medium was changed. Selection of stable clones was started 24 h
later with the addition of 3mg/ml of puromycin.
Microscopy
Cellular morphology was evaluated in proliferating and
differentiated cells after 50mM Sirtinol treatment for 24 h by phase
contrast microscopy without preliminary ﬁxation. Pictures were
produced using an inverted microscope (NIKON Eclipse
TE2000U) and a digital camera (NIKON DS5Mc).
Western blotting
Cells were harvested, washed twice in PBS and resuspended in a
volume of lysis buffer (50mM Tris pH 7.4, 5mM EDTA, 250mM
NaCl, 50mM NaF, 0.1% Triton X-100, 10mg/ml leupeptin and
1mM phenylmethylsulfonyl ﬂuoride). After 30min on ice, lysates
were centrifuged and protein collected. Protein concentrations
were measured by the Bradford assay (Bio-Rad Laboratories,
Hercules, CA). Proteins were normalized to 100mg/lane and
applied to SDS–polyacrylamide gels. The gels were blotted (1:30 h
at 230mA) onto a Hybond-ECL nitrocellulose ﬁlter (Amersham
Life science, Inc., ArlingtonHeights, IL). A Kaleidoscope prestained
protein solution (Bio-Rad Laboratories) was used as a molecular
weight standard. The ﬁlter was washed twice with TBS-0.1%
Tween-20 buffer (TBS-T), before blocking non-speciﬁc binding
sites with 5% milk /TBS-T for 1 h. The ﬁlter then was incubated for
1 h at room temperature with the speciﬁc antibody diluted in 3%
milk/TBS-T. The nitrocellulose ﬁlter was washed twice and
incubated with horseradish peroxidase-conjugated goat anti-
mouse or anti-rabbit. Detection was performed at room
temperature using the ECL method.
Flow cytometry
For proliferative studies, cells (5 105) were plated in 10mm
dishes. The following day the cells were treated with 0.5mM STS,
7.5mM thapsigargin, 1M sorbitol and 25mM camptothecin for the
times indicated in Figures 2C and 3. After the treatment, the cells
were harvested by centrifugation (10min at 1,600 rpm at 48C),
washedwith 5ml PBS, and resuspended in 500ml PBS towhich 5ml
of cold 70% EtOH was slowly added while stirring. Following
overnight incubation at 48C, cellswere centrifuged at 1,600 rpm for
5min at 48C and washed once with PBS. The cells were then
resuspended in 500ml of a solution composed by 50mg/ml PI,
250mg/ml RNase A and PBS 1 and kept at 378C for 30min. DNA
content was analyzed on a COULTER EPICS XL ﬂow cytometer
(Beckman Coulter, Fullerton, CA).
Statistical analysis
All experiments were repeated 3–5 times and the mean and the
standard error of the mean [SEM] were determined. Signiﬁcant
differences between sets of values for control and test groupswere
assessed by using Student’s t-test. A P-value refers to a comparison
of ameasured parameter in the experimental groupwith that of the
appropriate control; signiﬁcance was set at P< 0.05.
Results
Differentiated NG108-15 neurons are resistant to
Sirtinol treatment and express less SIRT1 than NG108-
15 cells
To test SIRT1 role in neuronal survival, we tested the toxicity of
the SIRT1 inhibitor sirtinol, on NG108-15 cells. Cultures were
grown in proliferating or differentiating conditions. Cells were
either left untreated (C) or treatedwith 50mM sirtinol for 24 h.
Figure 1A shows light microscope pictures of treated and
untreated cells. Cell death percentage was measured by ﬂow
cytometry. Sirtinol treatment killed about 79.5%of proliferating
cells. By contrast, only 32.1% of cell death was measured in
neuronal differentiated NG108-15 cells exposed to sirtinol.
We hypothesized that sirtinol resistance of NG108-15
differentiated cells could be due to a reduced expression of
SIRT1. Therefore, we measured SIRT1 expression in in vitro
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neuronal differentiated cells. As Figure 1B shows, SIRT1 levels
decreased in differentiated NG108-15 cells compared to their
proliferating counterpart.
SIRT1 overexpression and silencing in NG108-15 cells
affects cellular differentiation and stress response
To assess the role of SIRT1 in cellular differentiation and stress
resistance, a clone of NG108-15 cells stably overexpressing
SIRT1 (clone 8) as well as a clone in which SIRT1 was stably
silenced (clone 645) by shRNA transduction were produced.
SIRT1 levels in overexpressing and silenced SIRT1 clones are
shown in Figure 1C.
To conﬁrm SIRT1 overexpression and silencing, we
measured global protein lysine acetylation cellular levels inwt as
well as in overexpressing and silenced SIRT1 clones. As
Figure 1D (lanes 2 and 5) shows, cellular acetylation was
decreased both in proliferating and differentiated SIRT1
overexpressing cells compared to the wt NG108-15 cells. By
contrast, both proliferating and differentiated SIRT1 silenced
cells showed a higher level of total protein acetylation
(Fig. 1D lanes 3 and 6). To further conﬁrm that SIRT1
expression manipulation resulted in an increased or decreased
SIRT1 deacetylation activity, the acetylation state of p53 was
measured in wt, SIRT1 overexpressing and SIRT1 silenced cells
in proliferating and differentiating culture conditions (Fig. 1E).
As expected p53 acetylation was decreased in SIRT1
overexpressing cells and increased in SIRT1 silenced cells
comparing to wt cells.
Since we have observed a decrease in SIRT1 levels after
NG108-15 differentiation, we decided to study if also the
opposite was true, that is if NG108-15 differentiation could be
inﬂuenced by increasing or decreasing SIRT1 levels.
Figure 2A shows that the typical neuronal network of wt
NG108-15 differentiated cells (left part) was reduced in SIRT1
overexpressing clones (middle part) and increased in SIRT1
silenced cells (right part). NG108-15 differentiation was also
measured through the expression of the neuronal marker
MAP5. Figure 2B shows that MAP5 expression levels were
reduced in SIRT1 overexpressing cells and increased in SIRT1
silenced cells. Notably, MAP5 was abundantly expressed in
proliferating SIRT1 silenced cells (Fig. 2B).
To study SIRT1 involvement in neuronal stress resistance,
cell death induced by several stimuli was measured in wt, SIRT1
overexpressing and SIRT1 silenced NG108-15 cells.
Figure 2C shows that, as previously observed by us (Pucci et al.,
2008), differentiation of wt NG108-15 cells increased
resistance to 0.5mM STS with a percentage of cell killing of 18%
after 6 h and 37% after 16 h treatment. Overexpression of
SIRT1 reduced such resistance to STS. STS killed 35% after 6 h
and 57% after 16 h of differentiated SIRT1 overexpressing cells.
On the other hand, SIRT1 silencing increased resistance to STS
cell death after differentiation with only 8% after 6 h and 12%
after 16 h of cells being killed (Fig. 2C). Importantly, SIRT1
Fig. 3. SIRT1 effects on cell death induced by thapsigargin,
camptothecin, and sorbitol. Proliferating and NaB differentiated wt
and SIRT1 overexpressing cells were either left untreated or treated
with thapsigargin, camptothecin, or sorbitol for the indicated times.
Percentage of cell death wasmeasured by ﬂow cytometry analysis, as
described in Materials and Methods Section. CU control untreated
cells. M, signiﬁcantly different from thapsigargin treated wt cells. ^,
signiﬁcantly different from sorbitol treated wt cells. #, signiﬁcantly
different from camptothecin treated wt cells. Signiﬁcance was set at
P<0.05. Error bars represent standard deviation (SD). Results in each
part are the average of three independent experiments.
Fig. 2. SIRT1 effects on both neuronal differentiation and STS-
induced cell death in NG108-15 cells. A: Wt, SIRT1 overexpressing
and SIRT1 silenced cells were NaB differentiated. Morphology was
evaluated in differentiated cells by phase contrast microscopy.
Pictures were taken at 20T with a digital camera on an inverted
microscope. B: Proliferating and NaB differentiated wt, SIRT1
overexpressing and SIRT1 silenced cells were lysed and
differentiationmeasured byMAP5 expression as reported inMaterial
and Methods Section. b-actin was used as loading control. C:
Proliferating and NaB differentiated wt, SIRT1 overexpressing and
SIRT1 silenced cellswere either left untreatedor treatedwithSTS for
the indicated times. Percentage of cell death was measured by ﬂow
cytometry analysis, as described in Materials and Methods Section.
CU control untreated cells. M, P<0.05. Error bars represent standard
deviation (SD). Results in each part are the average of three
independent experiments.
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silencing signiﬁcantly reduced cell killing of proliferating cells. In
fact, 16 h STS treatment killed about 80% of wt and SIRT1
overexpressing cells and only 63.4% of SIRT1 silenced cells
(Fig. 2C).
To rule out the possibility that the results described above
were restricted to the particular selected clones, neuronal
viability after STS treatment was also studied using additional
SIRT1 overexpressing and SIRT1 silenced NG108-15 clones.
Supplementary Figure 1 shows that the analysis of two different
SIRT1 overexpressing (clones 7 and 9) and one SIRT1 silenced
clone (clone 646) produced comparable results in terms of cell
viability.
Sirt1 effect on neuronal viability was independent of cell
death stimulus. Cell death was measured by ﬂow cytometry
after treatment with 7.5mM thapsigargin (48 h), 1M sorbitol
(6 h), and 25mM camptothecin (48 h). As Figure 3 shows
differentiated cells were in general more resistant to cell death.
Importantly, SIRT1 overexpressing, proliferating and
differentiated, cells were more sensitive than wt cells to
thapsigargin and sorbitol. Camptothecin-induced cell death
increased only in differentiated SIRT1 overexpressing cells.
SIRT1 effect on cell cycle was also investigated. SIRT1
overexpression induced a statistically signiﬁcant decrease of
G0/G1 percentage in proliferating cells, compared to WT cells
(Fig. S2). Also in differentiated cells SIRT1 overexpression
induced a statistically signiﬁcant reduction of G0/G1 cells,
associated to an increase in the percentage of cells in S phase
(Fig. S2). No effect on cell cycle was observed when SIRT1 was
silenced.
IGF-1 and IGF-1R expression levels are regulated by
SIRT1
Our data showed a role for IGF-1 in inducing cell death
resistance (Pucci et al., 2008), and a negative effect of SIRT1 in
cellular resistance (Figs. 2C and 3). Therefore, we hypothesized
an interplay between IGF-1 and SIRT1 pathways to regulate
neuron resistance. To pursue this goal, secreted and
intracellular IGF-1 levels were measured in wt, SIRT1
overexpressing and SIRT1 silenced cells. Figure 4A shows that
IGF-1 secretion was increased by STS treatment in wt NG108-
15 cells after 16 h of STS treatment. The increase is particularly
evident in differentiated cells. Differentiated SIRT1 silenced
cells secreted IGF-1 in the absence of STS treatment. The
presence of STS increased such release both after 6 and 16 h
(Fig. 4A).On the contrary, SIRT1overexpressing cells showed a
reduced IGF-1 secretion after STS treatment in proliferating
cells compared to wt cells (Fig. 4A). In differentiated SIRT1
overexpressing cells IGF-1 secretion was induced by STS only
after 16 h of treatment (Fig. 4A). Intracellular IGF-1 was also
measured. Interestingly, SIRT1 silenced cells showed a
signiﬁcant increase in IGF-1 intracellular expression after STS
treatment compared to wt cells. Moreover, both proliferating
and differentiated SIRT1 silenced cells had an increased basal
expression of intracellular IGF-1 compared to wt and SIRT1
overexpressing cells (Fig. 4B). On the contrary, SIRT1
overexpressing cells had a decreased expression of intracellular
IGF-1 compared to wt and to SIRT1 silenced cells after STS
treatments (Fig. 4B). Since activation of the IGF-1 pathway
depends also on IGF-1R expression, IGF-1R protein levels were
measured in proliferating and differentiated wt, SIRT1
overexpressing and SIRT1 silenced cells in the presence or
absence of STS. Figure 5A shows that proliferating SIRT1
silenced cells express more IGF-1R compared to wt, while
SIRT1 overexpressing cells express less IGF-1 receptor thanwt
cells. STS treatment did not substantially alter such differences.
In differentiated cells (Fig. 5B), IGF-1R expression was
comparable among wt, SIRT1 overexpressing and SIRT1
silenced control cells. STS treatment induced an increase in
IGF-1R expression in SIRT1 silenced cells. On the contrary,
IGF-1R expression decreased after STS treatment in wt cells
and more clearly in SIRT1 overexpressing cells (Fig. 5B).
Fig. 4. IGF-1 expression and secretion in SIRT1 overexpressing and silenced cells. A: Proliferating and NaB differentiated wt, SIRT1
overexpressing and SIRT1 silenced cells were either left untreated or treated with STS for the indicated times. Secreted IGF-1 levels were
measured byWestern blot after cellular culturemediumcollection and concentration as indicated inMaterial andMethods Section. CU control
untreated cells. B: Proliferating andNaB differentiated wt, SIRT1 silenced, and SIRT1 overexpressing cells were either left untreated or treated
withSTSforthetimes indicated. Intracellular IGF-1expression levelsweremeasuredbyWesternblot.b-actinwasusedas loadingcontrol.Results
are representative of three independent experiments.
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Increased AKT and ERK1/2 phosphorylation in SIRT1
silenced cells
Since IGF-1 and IGF-1R are more expressed in differentiated
SIRT1 silenced NG108-15 cells compared to wt or SIRT1
overexpressing cells, we sought to determine if also the
activation of downstream AKT and ERK1/2 kinases was
increased in SIRT1 silenced cells. Therefore, wt, SIRT1
overexpressing and SIRT1 silenced cells were differentiated and
then either left untreated or treatedwith STS. AKT and ERK1/2
activation was measured by determining phosphorylation
levels. Figure 6A shows an increased phosphorylation of AKT
on Tyrosine 308 in SIRT1 silenced cells after 30min of STS
treatment compared with wt cells. By contrast, no increase in
AKT phosphorylation was observed in SIRT1 overexpressing
cells (Fig. 6A). Total AKT levelswere not affected by both SIRT1
overexpression or silencing and by STS addition (Fig. 6A).
Similarly, ERK1/2 phosphorylation on Threonine 202/Tyrosine
204 was increased in wt, SIRT1 overexpressing cells and in
SIRT1 silenced cells. The increased phosphorylation was more
evident in SIRT1 silenced cells after 60 and 120min of STS
treatment (Fig. 6A). It is worth noting that, also total ERK1/2
levels were increased in SIRT1 silenced cells after STS
treatment compared to wt and SIRT1 overexpressing cells.
Densitometry analysis of AKT phosphorylation in wt, SIRT1
overexpressing and SIRT1 silenced cells is shown in
Figure 6B. Figure 6C,D shows densitometric analysis of ERK1/2
phosphorylation on Thr202 and in Tyr204, respectively.
Discussion
This study showed that downregulation of SIRT1 protein
expression increased neuronal resistance to cell death by
activating IGF-1 signaling and consequently AKT and ERK pro-
survival pathways. We demonstrated that neuronal secreted
IGF-1 levels are inﬂuenced by SIRT1 protein levels in in vitro
differentiated neurons. Our results indicated an IGF-1
neuroprotective role and a SIRT1 neurotoxic effect.
Initially, we investigated SIRT1 role in differentiated neurons
observing the effect of sirtinol, a SIRT1 inhibitor. Sirtinol was
indeed highly toxic in proliferating neuroblasts. Sirtinol toxicity
was dramatically reduced in differentiated cells (Fig. 1A). SIRT1
expression in in vitro terminally differentiated neurons was
measured. Our results showed that SIRT1 expression
decreased in differentiated neurons, compared to their
proliferating counterpart (Fig. 1B). A decrease of SIRT1
expression in terminally differentiated cells has been observed
previously in a muscle differentiation model (Fulco et al., 2003)
and in adipogenesis (Picard et al., 2004). From our previous
studies we knew that differentiated neuronal cells are more
resistant to STS treatment than their proliferating counterpart
(Pucci et al., 2008). To understand if SIRT1 decrease in
differentiated neurons could be responsible of such acquired
cell resistance to STS, we produced SIRT1-silenced and
overexpressing clones (Figs. 1C and S1). Silencing and
overexpressing SIRT1 did inﬂuence p53 acetylation state. A
decrease of p53 acetylation was observed in proliferating and
differentiated SIRT1 overexpressing cells. On the contrary an
increase of p53 acetylation was observed when SIRT1
expression was silenced (Fig. 1E). Interestingly, SIRT1 silencing
had a positive effect on neuronal differentiation promoting
neuronal net formation (Fig. 2A) and the increase of MAP5
(Fig. 2B). On the contrary, SIRT1 overexpression inhibited
neuronal differentiation (Fig. 2A,B). Importantly, SIRT1
overexpression increased neurons sensitivity to STS,
thapsigargin, camptothecin, and sorbitol (Figs. 2C and 3). SIRT1
has been indicated as neurotoxic also in other studies. SIRT1
overexpression in mice induced a memory deﬁcit, and had no
neuroprotective effects against damage induced by ischemia or
by MPTP (Kakefuda et al., 2009). Moreover, Li et al. (2008)
showed that SIRT1 inhibition protects neurons from oxidative
stress. Experiments performed using SIRT1 chemical inhibitors
highlighted that inactivation of SIRT1was beneﬁcial for neurons
(Fulco et al., 2003). In particular, nicotinamide promoted
neuronal survival after acute anoxic injury and ﬂuid percussion
injury (Chong et al., 2005; Holland et al., 2008). Finally, it has
been shown that nicotinamide and sirtinol increases the
resistance to glutamate and N-methyl-D-aspartate (NMDA)-
induced excitotoxicity (Liu et al., 2008, 2009).
Our work showed that in differentiated SIRT1
overexpressing cells, the decrease of G0/G1 cells was
associated to an increase of S phase cells indicating a positive
effect of SIRT1 on proliferation and cell cycling. Indeed, SIRT1
overexpressing cells showed a decreased ability to differentiate
Fig. 5. IGF-1R expression in wt, SIRT1 overexpressing, and SIRT1 silenced cells. A: Proliferating wt, SIRT1 overexpressing and SIRT1 silenced
cells were either left untreated or treated with STS for 6 h. IGF-1R levels weremeasured byWestern blot as indicated in Materials andMethods
Section.CU controluntreatedcells.B:NaBdifferentiatedwt,SIRT1overexpressing,andSIRT1silencedcellswereeither leftuntreatedortreated
withSTSfor6 h.IGF-1RlevelsweremeasuredbyWesternblotasindicatedinMaterialsandMethodsSection.CU controluntreatedcells.Results in
each part are representative of three independent experiments.
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once treated with NaB (Fig. 2A central part). In SIRT1
proliferating cells the decrease in the percentage of G0/G1 cells
was probably due to an increase in cell death associated to
SIRT1 overexpression (Fig. 2C). The positive effect of SIRT1 on
cell cycle has been also observed by Rathbone et al. (2009).
Since our previous work indicated that IGF-1 signaling
positively inﬂuences cell survival in STS-treated neurons (Pucci
et al., 2008), we investigated the correlation among SIRT1
expression and IGF-1 regulation in neuronal survival. We
showed that, once treated with STS, IGF-1 expression and
secretion increased in differentiated neurons compared to
proliferating cells (Fig. 4). Such increase was more evident in
SIRT1 silenced cells that expressed more IGF-1 even in
proliferating conditions (Fig. 4).
Also IGF-1R expression levels were altered by SIRT1
expression manipulation (Fig. 5). In proliferating cells
overexpressing or silencing SIRT1 induced respectively a
decrease or an increase of IGF-1R expression in presence and in
absence of STS treatment. In particular in SIRT1 silenced cells
STS treatment induced an increase of IGF-1R (Fig. 5).
Considering our results on IGF-1 and IGF-1R, we tested the
hypothesis that SIRT1 could inﬂuence IGF-1 pathway activation.
As expected, AKT phosphorylation was strongly increased in
SIRT1 silenced cells respect to wt cells (Fig. 6A,B). By contrast,
in SIRT1 overexpressing cells AKT phosphorylation decreased
during the treatment. It can be concluded that SIRT1 turns off
IGF-1 activated AKT pathway. Indeed, AKT pathway resulted
strongly activated in absence of SIRT1. ERK1/2 is also activated
by IGF-1 (Laviola et al., 2007). In our system ERK1/2
phosphorylation increased in wt cells during STS treatment
(Fig. 6A,C). The activation of ERK1/2 pathway, measured as
Thr202/Tyr204 phosphorylation, was strongly augmented
when SIRT1 expression was silenced (Fig. 6A,C). On the other
hand, Thr202/Tyr204 phosphorylationon ERK1/2was inhibited
in SIRT1 overexpressing cells (Fig. 6A,C). These results
conﬁrmed that SIRT1 silencing in in vitro differentiated neurons
enables the activation of AKT and ERK1/2 pathways.
Several published studies have shown that IGF-1 has a
neurotrophic and neuroprotective role in central nervous
system (Taguchi et al., 2007; Pucci et al., 2008; Broughton and
Partridge, 2009). Our work indicated that downregulation of
SIRT1 expression conferred resistance to STS induced cell
death by augmenting IGF-1 survival pathways. Also Li et al.
(2008) showed that SIRT1 inhibition can confer resistance to a
cellular stress. In particular, they showed that SIRT1 inhibition
induces resistance to neurons in presence of oxidative stress.
However, in their system SIRT1 inhibition attenuates ERK1/2
activation by reducing IGF-1 signaling.On the contrary, herewe
observed that SIRT1 inhibition induced IGF-1 signaling. The
contrasting data on IGF-1 pathway activation are probably
explained by the fact that STS induces mostly apoptosis.
Differently, oxidative stress induces mostly necrosis.
Therefore, IGF-1 signaling can be differently regulated during
necrosis or apoptosis. Indeed, the study by Li et al. (2008) did
not highlight AKT activation as our results instead did.
Our study shows that in neurons the reparative role of IGF-1
is profoundly ameliorated in the absence of SIRT1 expression.
Interestingly, SIRT1 silenced cells maintained IGF-1 secretion
and IGF-1 receptor expression even in the presence of a cell
death stimuli (STS). Such observation suggests that SIRT1
silencing by molecular or chemical strategies could increase the
survival rate of damaged neurons though the IGF-1 pathway.
Therefore, our work sets the foundations for mechanistic and
pharmacological studies that, in a not so distant future, will help
to understand if inhibition of SIRT1 expression and/or activity
by new compounds can be used to reduce neuronal loss
characteristic of neurodegenerative diseases.
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